Abiopharma

🔍 EVRAN SEDAT (Executive)

Company: BIO-RAD LABORATORIES, INC. (BIO BIO.B)

Report Date: 2025-09-05

Detailed Transactions and Holdings:

• Acquired 864 shares of Bio-Rad A Common Stock (Direct)
  Date: 2025-09-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,800.85 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 277 shares of Bio-Rad A Common Stock at $295.43 per share (Direct)
  Date: 2025-09-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,523.85 | transaction_form_type: 4
• Acquired 4,110 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,110.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Sold 864 shares of Restricted Stock Units (Derivative)
  Date: 2025-09-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,592.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
• F2: Includes 56.9880 and 26.7190 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2025 and 06/30/2025, respectively.
• F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
• F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.